Terms: = Head and neck cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Diagnosis
7 results:
1. Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and their Role in the Treatment of cancer: A Review.
Unnisa A; Chettupalli AK; Hussain T; Kamal MA
Anticancer Agents Med Chem; 2022; 22(20):3370-3381. PubMed ID: 35400324
[TBL] [Abstract] [Full Text] [Related]
2. miR-326 inhibits the progression of papillary thyroid carcinoma by targeting MAPK1 and erbb4.
Nie FR; Li QX; Wei HF; Ma Y
Neoplasma; 2020 May; 67(3):604-613. PubMed ID: 32266816
[TBL] [Abstract] [Full Text] [Related]
3. Relevance and actionable mutational spectrum in oral squamous cell carcinoma.
Jayaprakash C; Varghese VK; Jayaram P; Chakrabarty S; Kudva A; Ray S; Satyamoorthy K
J Oral Pathol Med; 2020 May; 49(5):427-434. PubMed ID: 31845386
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Cavalieri S; Perrone F; Miceli R; Ascierto PA; Locati LD; Bergamini C; Granata R; Alfieri S; Resteghini C; Galbiati D; Busico A; Paielli N; Patuzzo R; Maurichi A; Gallino G; Ruggeri R; Mariani L; Palla M; Licitra L; Bossi P
Eur J Cancer; 2018 Jul; 97():7-15. PubMed ID: 29734047
[TBL] [Abstract] [Full Text] [Related]
5. Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management.
Ribeiro IP; Marques F; Caramelo F; Pereira J; Patrício M; Prazeres H; Ferrão J; Julião MJ; Castelo-Branco M; de Melo JB; Baptista IP; Carreira IM
Cell Oncol (Dordr); 2014 Feb; 37(1):29-39. PubMed ID: 24353162
[TBL] [Abstract] [Full Text] [Related]
6. [Long term results following radiation therapy of locally recurrent and metastatic malignant melanoma].
Seegenschmiedt MH; Keilholz L; Altendorf-Hofmann A; Pieritz A; Urban A; Schell H; Hohenberger W; Sauer R
Hautarzt; 1999 Aug; 50(8):572-9. PubMed ID: 10460301
[TBL] [Abstract] [Full Text] [Related]
7. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience.
Seegenschmiedt MH; Keilholz L; Altendorf-Hofmann A; Urban A; Schell H; Hohenberger W; Sauer R
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):607-18. PubMed ID: 10348291
[TBL] [Abstract] [Full Text] [Related]
